{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:55:04Z","timestamp":1778903704170,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013050","name":"New England Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016473","name":"American Regent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018559","name":"Aileron Therapeutics","doi-asserted-by":"publisher","award":["NCT02158572"],"award-info":[{"award-number":["NCT02158572"]}],"id":[{"id":"10.13039\/100018559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.contraception.2020.11.011","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T18:23:31Z","timestamp":1606587811000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results"],"prefix":"10.1016","volume":"103","author":[{"given":"Anita L","family":"Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M","family":"Kaunitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred N","family":"Poindexter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald T","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Flood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Joseph A","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth IO","family":"Garner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.11.011_bib0001","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/14656566.2015.1022531","article-title":"Transdermal contraception methods: today's patches and new options on the horizon","volume":"16","author":"Nelson","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.contraception.2020.11.011_bib0002","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2020.11.011_bib0003","series-title":"Final summary minutes: Advisory Committee for Reproductive Health Drugs meeting","year":"2007"},{"key":"10.1016\/j.contraception.2020.11.011_bib0004","series-title":"Establishing effectiveness and safety for hormonal drug products intended to prevent pregnancy: guidance for industry","year":"2019"},{"key":"10.1016\/j.contraception.2020.11.011_bib0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.contraception.2011.10.006","article-title":"Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial","volume":"85","author":"Archer","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.11.011_bib0006","series-title":"TWIRLA (levonorgestrel and ethinyl estradiol) transdermal system [prescribing information]","year":"2020"},{"key":"10.1016\/j.contraception.2020.11.011_bib0007","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2020.11.011_bib0008","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.contraception.2015.07.016","article-title":"Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis","volume":"92","author":"Yamazaki","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.11.011_bib0009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.contraception.2011.09.019","article-title":"Predictors of noncompliance in an oral contraceptive clinical trial","volume":"85","author":"Westhoff","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.11.011_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.whi.2017.09.010","article-title":"Pregnancy intention and contraceptive use among women by class of obesity: results from the 2006-2010 and 2011-2013 National Survey of Family Growth","volume":"28","author":"Nguyen","year":"2017","journal-title":"Womens Health Issues"},{"key":"10.1016\/j.contraception.2020.11.011_bib0011","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1016\/S2214-109X(19)30265-7","article-title":"Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials","volume":"7","author":"Archer","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.contraception.2020.11.011_bib0012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.contraception.2014.01.013","article-title":"Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel\/ethinyl estradiol combined oral contraceptive","volume":"89","author":"Portman","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.11.011_bib0013","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2006.07.005","article-title":"Evaluation of a continuous regimen of levonorgestrel\/ethinyl estradiol: phase 3 study results","volume":"74","author":"Archer","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.11.011_bib0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2007.06780.x","article-title":"Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations","volume":"139","author":"Pomp","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.contraception.2020.11.011_bib0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1472-6874-9-18","article-title":"Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol\/norelgestromin contraceptive patch in Italy","volume":"9","author":"Crosignani","year":"2009","journal-title":"BMC Womens Health"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420304340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420304340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:17:37Z","timestamp":1757881057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782420304340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0010782420304340"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.11.011","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}